INDEX TO VOLUME 170

Author Index

Abachin, E., 701
Abakar, A. Z., 955
Abdalla, R. E., 1037
Abdelnour, A., 94
Abrams, J. S., 939
Addiss, D. G., 403
Adegbola, R. A., 1316
Agbanyo, F. R., 1120
Agoki, E., 313
Ahearn, J. M., 429
Ahmed, A., 517
AIDS Clinical Trial Research Group 047, 1165
AIDS Clinical Trials Group 029/031 Research Team, 165
Akaike, T., 1023
Akil, B., 165
Albert, J., 1367
Albert, M. J., 256
Alberti, A., 1042
Alexander, J. P., 986
Ali-Salaam, P., 500
Al-Janadi, M., 1037
Allen, R. C., 1463
Almiron, M., 1570
Alpers, M. P., 1339
Amadori, A., 1148
Ammons, W. S., 1473
Amstey, M. S., 251
Anaissie, E. J., 384
Andersen, L. P., 135
Anderson, L. J., 795, 986
Anderson, R. E., 1157
Anderson, W. R., 457
Andersson, B., 678
Ando, T., 439
Andreone, P., 1042
Angel, C. S., 600
Anthony, B. F., 717
Antic, R., 1052
Aperia, K., 1367
Apicella, M., 254
Araneo, B., 1046
Arita, M., 1049
Armstrong, D., 1394
Artelt, A., 223
Artenstein, A., 834
Arvin, A., 1068
Ashkenazi, A., 1323
Ashley, R. L., 20
Atoui, N., 1376
Atzori, C., 1349
Atzpodien, E., 223
Aurelius, E., 678
Autenrieth, I. B., 140
Avery, D. T., 1326
Awadzi, K., 1054
Aziz, N., 1165
Bacellar, H., 1284
Badaró, F., 413
Badaró, R., 413
Badon, S. J., 231
Baenziger, J., 1288
Bailey, R. L., 709
Baker, C. J., 88, 1316
Balachandra, K., 746
Balfour, H. H., Jr., 68
Balish, E., 180, 390, 900
Balwit, J. M., 1033
Banatvala, N., 1634
Banerjee, S. N., 1622
Barditch-Crovo, P. A., 1394
Barelli, A., 1148
Barnum, G., 20
Baron, P. A., 1394
Barraez, T., 396
Barras, C., 1319
Barrett, L., 1334
Barrett, T. J., 468
Barthold, S. W., 500, 1312
Bartok, A. E., 157, 488
Bassiakos, Y., 189
Bastian, I. B., 1353
Batt, K., 425
Batts, D. H., 1009
Bauer, H. M., 1077
Baughman, R., 165
Baumgärtner, W., 223
Baxa, D. M., 202
Baylor, M., 1606
Bean, N. H., 128, 468
Beasley, R. P., 1418
Beattie, D. T., 1518
Bechtold, C. M., 1157
Beck, M. A., 351
Beckers, C., 918
Bellini, W. J., 795, S15
Belshe, R. B., 782
Benhamou, J. P., 433
Berche, P., 701
Berger, M., 82
Berkelman, R. L., 272
Bernard, H.-U., 1077, 1086
Bernardi, M., 1042
Berthold, P., 1053
Berti, Y. G., 396
Berzofsky, J. A., 334
Besh, S., 927
Besley, D. R., 1284
Besser, T. E., 253, 1606
Besson, M., 479
Bettin, K. M., 615
Bhamarapravati, N., 27
Bhatnagar, N., 841
Bhattacharjee, A. K., 622
Bianco, C., 206
Billman-Jacobe, H., 1326
Birkholz, S., 135
Biron, K. K., 68
Bissuel, F., 749
Black, J., 165
Black, K. M., 1490
Blagdon, M., 1439
Blake, C., 894
Blattner, W., 334
Bockenstedt, L. K., 500
Bodey, G. P., 1344
Bogaerts, H., 705
Bohach, G. A., 609
Boiocchi, M., 211
Boivin, G., 68
Bolognesi, D. P., 782
Bonardet, A., 1376
Bond, M., 1524
Böni, J., 318, 1384
Borg, A. J., 1047
Borges, R., 396
Borges, R. E., 396
Borja, J., 1344
Borkowsky, W., 1003
Borri, A., 1148
Bosch, F. X., 1093, 1424
Bourbeau, P. P., 227
Boursnell, M. E. G., 1100
Boyce, J. M., 1539
Boylen, C. T., 165
Bozzette, S. A., 238, 1601
Boßhammer, J., 1616
Braddick, M., 1134
Braga, C., 927
Brambilla, D., 996
Branger, M., 433
Brattig, N. W., 955
Braun, D. G., 1384
Bredius, R. G. M., 848
Bremell, T., 94
Brenes, M. M., 753
Brewer, M. A., 476
Bricmont, P., 1394
Britton, W. J., 1326
Broome, C. V., 693
Bross, J. E., 227
Brown, A. E., 1626
Brown, D. R., 759
Brummer, E., 173
Brun-Pascaud, M., 653
Bryan, J. P., 517
Bryan, J. T., 759
Bryan, R. T., 494
Bryant, A. E., 1463
Bryson, Y., 1279
Buchbinder, S. P., 198
Buciak, J., 563
Buisman, A. M., 234
Bulkow, L. R., 368, 461
Bunting, S. A., 1323
Burczak, J. D., 1308
Burk, R. D., 1404, 1418
Burke, R. L., 1110
Burkot, T. R., 883
Burman, L. Å., 220
Burwen, D. R., 1622
Buscemi, S., 1637
Bush, C. E., 202
Buurman, W. A., 1483
Byrne, C., 1141
Cable, R. G., 231
Cabrera, A., 1007
Caiaffa, W. T., 1636
Calandra, G., 510
Calandra, T., 1319
Calderón, E. J., 1041
California Collaborative Treatment Group, 238
Callister, S. M., 115, 499
Cambau, E., 479
Cameron, M. L., 60
Camp, B., 488
Campetella, O., 1570
Campos, J., 453
Capel, P. J. A., 854
Cappello, M., 918
Cappuccinelli, P., 750
Carbon, C., 1331
Carbone, A., 211
Carcamo, C., 439
Carias, L. L., 1539
Carman, W. F., 1300
Carme, B., 257
Carreño, V., 669
Carrera-Zandomeni, M., 787
Carroll, S., 996
Cartel, J. L., 247
Cartter, M. L., 693
Carvalho, J. S., 413
Caserta, M. T., 1586
Cassai, E., 211
Castillo, I., 669
Cavaillon, J.-M., 1490
Centurion-Lara, A., 1334
Cernescu, C. E., 1043
Challanain, D. N., 1100
Chamoux, C., 377
Chamow, S. M., 1323
Chan, S.-Y., 1077
Chandra, R., 325
Chang, D.-M., 811
Chang, N. T., 1384
Chang, S.-J., 76
Chanteau, S., 247
Chao, C. C., 457
Chapman, P. A., 251
Chappell, C. L., 419
Charlebois, E. D., 308
Chau, F., 653
Chaves, C. S., 494

INDEX TO VOLUME 170

Author Index

Abachin, E., 701
Abakar, A. Z., 955
Abdalla, R. E., 1037
Abdelnour, A., 94
Abrams, J. S., 939
Addiss, D. G., 403
Adegbola, R. A., 1316
Agbanyo, F. R., 1120
Agoki, E., 313
Ahearn, J. M., 429
Ahmed, A., 517
AIDS Clinical Trial Research Group 047, 1165
AIDS Clinical Trials Group 029/031 Research Team, 165
Akaike, T., 1023
Akil, B., 165
Albert, J., 1367
Albert, M. J., 256
Alberti, A., 1042
Alexander, J. P., 986
Ali-Salaam, P., 500
Al-Janadi, M., 1037
Allen, R. C., 1463
Almiron, M., 1570
Alpers, M. P., 1339
Amadori, A., 1148
Ammons, W. S., 1473
Amstey, M. S., 251
Anaissie, E. J., 384
Andersen, L. P., 135
Anderson, L. J., 795, 986
Anderson, R. E., 1157
Anderson, W. R., 457
Andersson, B., 678
Ando, T., 439
Andreone, P., 1042
Angel, C. S., 600
Anthony, B. F., 717
Antic, R., 1052
Aperia, K., 1367
Apicella, M., 254
Araneo, B., 1046
Arita, M., 1049
Armstrong, D., 1394
Artelt, A., 223
Artenstein, A., 834
Arvin, A., 1068
Ashkenazi, A., 1323
Ashley, R. L., 20
Atoui, N., 1376
Atzori, C., 1349
Atzpodien, E., 223
Aurelius, E., 678
Autenrieth, I. B., 140
Avery, D. T., 1326
Awadzi, K., 1054
Aziz, N., 1165
Bacellar, H., 1284
Badaró, F., 413
Badaró, R., 413
Badon, S. J., 231
Baenziger, J., 1288
Bailey, R. L., 709
Baker, C. J., 88, 1316
Balachandra, K., 746
Balfour, H. H., Jr., 68
Balish, E., 180, 390, 900
Balwit, J. M., 1033
Banatvala, N., 1634
Banerjee, S. N., 1622
Barditch-Crovo, P. A., 1394
Barelli, A., 1148
Barnum, G., 20
Baron, P. A., 1394
Barraez, T., 396
Barras, C., 1319
Barrett, L., 1334
Barrett, T. J., 468
Barthold, S. W., 500, 1312
Bartok, A. E., 157, 488
Bassiakos, Y., 189
Bastian, I. B., 1353
Batt, K., 425
Batts, D. H., 1009
Bauer, H. M., 1077
Baughman, R., 165
Baumgärtner, W., 223
Baxa, D. M., 202
Baylor, M., 1606
Bean, N. H., 128, 468
Beasley, R. P., 1418
Beattie, D. T., 1518
Bechtold, C. M., 1157
Beck, M. A., 351
Beckers, C., 918
Bellini, W. J., 795, S15
Belshe, R. B., 782
Benhamou, J. P., 433
Berche, P., 701
Berger, M., 82
Berkelman, R. L., 272
Bernard, H.-U., 1077, 1086
Bernardi, M., 1042
Berthold, P., 1053
Berti, Y. G., 396
Berzofsky, J. A., 334
Besh, S., 927
Besley, D. R., 1284
Besser, T. E., 253, 1606
Besson, M., 479
Bettin, K. M., 615
Bhamarapravati, N., 27
Bhatnagar, N., 841
Bhattacharjee, A. K., 622
Bianco, C., 206
Billman-Jacobe, H., 1326
Birkholz, S., 135
Biron, K. K., 68
Bissuel, F., 749
Black, J., 165
Black, K. M., 1490
Blagdon, M., 1439
Blake, C., 894
Blattner, W., 334
Bockenstedt, L. K., 500
Bodey, G. P., 1344
Bogaerts, H., 705
Bohach, G. A., 609
Boiocchi, M., 211
Boivin, G., 68
Bolognesi, D. P., 782
Bonardet, A., 1376
Bond, M., 1524
Böni, J., 318, 1384
Borg, A. J., 1047
Borges, R., 396
Borges, R. E., 396
Borja, J., 1344
Borkowsky, W., 1003
Borri, A., 1148
Bosch, F. X., 1093, 1424
Bourbeau, P. P., 227
Boursnell, M. E. G., 1100
Boyce, J. M., 1539
Boylen, C. T., 165
Bozzette, S. A., 238, 1601
Boßhammer, J., 1616
Braddick, M., 1134
Braga, C., 927
Brambilla, D., 996
Branger, M., 433
Brattig, N. W., 955
Braun, D. G., 1384
Bredius, R. G. M., 848
Bremell, T., 94
Brenes, M. M., 753
Brewer, M. A., 476
Bricmont, P., 1394
Britton, W. J., 1326
Broome, C. V., 693
Bross, J. E., 227
Brown, A. E., 1626
Brown, D. R., 759
Brummer, E., 173
Brun-Pascaud, M., 653
Bryan, J. P., 517
Bryan, J. T., 759
Bryan, R. T., 494
Bryant, A. E., 1463
Bryson, Y., 1279
Buchbinder, S. P., 198
Buciak, J., 563
Buisman, A. M., 234
Bulkow, L. R., 368, 461
Bunting, S. A., 1323
Burczak, J. D., 1308
Burk, R. D., 1404, 1418
Burke, R. L., 1110
Burkot, T. R., 883
Burman, L. Å., 220
Burwen, D. R., 1622
Buscemi, S., 1637
Bush, C. E., 202
Buurman, W. A., 1483
Byrne, C., 1141
Cable, R. G., 231
Cabrera, A., 1007
Caiaffa, W. T., 1636
Calandra, G., 510
Calandra, T., 1319
Calderón, E. J., 1041
California Collaborative Treatment Group, 238
Callister, S. M., 115, 499
Cambau, E., 479
Cameron, M. L., 60
Camp, B., 488
Campetella, O., 1570
Campos, J., 453
Capel, P. J. A., 854
Cappello, M., 918
Cappuccinelli, P., 750
Carbon, C., 1331
Carbone, A., 211
Carcamo, C., 439
Carias, L. L., 1539
Carman, W. F., 1300
Carme, B., 257
Carreño, V., 669
Carrera-Zandomeni, M., 787
Carroll, S., 996
Cartel, J. L., 247
Cartter, M. L., 693
Carvalho, J. S., 413
Caserta, M. T., 1586
Cassai, E., 211
Castillo, I., 669
Cavaillon, J.-M., 1490
Centurion-Lara, A., 1334
Cernescu, C. E., 1043
Challanain, D. N., 1100
Chamoux, C., 377
Chamow, S. M., 1323
Chan, S.-Y., 1077
Chandra, R., 325
Chang, D.-M., 811
Chang, N. T., 1384
Chang, S.-J., 76
Chanteau, S., 247
Chao, C. C., 457
Chapman, P. A., 251
Chappell, C. L., 419
Charlebois, E. D., 308
Chau, F., 653
Chaves, C. S., 494

Cheang, M., 313
Chen, C.-J., 498
Chen, D.-S., 1128
Chen, I., 1279
Chen, M., 500
Chen, P.-J., 1128
Chen, S., 1047
Chernesky, M. A., 1308
Chernoff, D., 1288
Cherry, J. D., 293
Chieco-Bianchi, L., 1148
Children's Vaccine Initiative Ad Hoc Committee on an Investment Strategy for Measles Control, S63
Chimabutra, K., 746
Chin, D. P., 362, 578
Chiu, C.-T., 1582
Chiu, C.-Y., 76
Chongsuphajaisiddhi, T., 971
Chou, C.-C., 775
Chow, A. W., 818
Chu, C.-M., 358, 1582
Chungue, E., 1304
Cillari, E., 1637
Cirillo, C., 1296
Clabots, C. R., 615
Clark, S. J., 194
Clausen, C. R., 1606
Cleary, J. D., 242
Clements, D. A., 1050
Clements, M. L., 510, 782
Clerici, M., 334
Coleman, R. L., 1288
Collins, H., 622
Collins, L. A., 644
Colman, N., 743
Colman, S. M., 44
Colmenares, C., 396
Colombo, M. M., 750
Colonno, R. J., 1157
Concepcion, I. E., 717
Concepcion, N. F., 717
Conge, A.-M., 1376
Conway, B., 766
Coombs, R. W., 553
Cooper, D. A., 1141
Cooper, J. A., 44
Cope, L. D., 867
Cordón-Rosales, C., 1630
Corey, L., 20, 782
Costanzo, M., 1586
Coster, T. S., 1518
Cotte, L., 749
Cotton, A., 622
Courtois, F., 433
Coutinho, A., 946
Cox, N. J., 1432
Craig, S., 194
Cramer, H., 759
Cravioto, A., 1610
Cross, A. S., 622, 834
Cryz, S. J., Jr., 834
Cumberland, W. G., 1165
Cumming, C., 1053
Cummings, P. K., 464
Cupps, T., 510
Curnutte, J. T., 1524
Cursaro, C., 1042
Cutts, F. T., S32
Daar, E. S., 194
Dalessio, J., 20
Danila, R. N., 254
Darouiche, R. O., 720
Datta, P., 1134
Davidson, J. M., 570
Davidson, M., 368, 461, 510
Davis, R., 165
Day, K. P., 1339
D'Costa, L. J., 313
de Almeida Filho, P. J., 927
de Andrade, A. P., 750
De Boer, M. L., 818
de Britton, R. M., 753
de Caceres, L. G., 396
Decker, S., 1053
Deeks, J. J., 1634
DeGirolami, P. C., 615
De Grave, D., 705
de Haas, M., 848, 854
Dekker, C. L., 1288
De La Fuente, L., 696
Delius, H., 1077
Del Mistro, A., 1148
de Lourdes Tosca, M., 693
De Maria, A., 1296
DeMaria, T. F., 1532
de Martino, M., 1000
Demitriou, R., 1566
de Montclos, M., 749
de Noya, B. A., 396
Dentener, M. A., 1483
de Q. Sousa, A., 494
de Queiroz, T. R. B. S., 494
De Re, V., 211
Deresinski, S. C., 157, 488
Derkx, B. H. F., 848
Derouin, F., 653
de Sanjosé, S., 1424
DesJardins, R., 1394
Detels, R., 293
Deveikis, A., 1279
de Vries, P., S42
Dewhurst, S., 1586
de Wit, T. P. M., 848
Dharakul, T., 27
Dhir, A., 720
Diagne, A., 563, 1279
Diaz, C., 996
Dickover, R. E., 1279
DiFerdinando, G. T., 151
Dignani, M. C., 384
Dillon, M., 1279
Di Luca, D., 211
Dimock, K. A., 403
Dixon, B., 500
Dobbins, J. G., 753
Dodin, A., 701
Dohmae, K., 1589
Dolan, M., 636
Dolcetti, R., 211
Dolin, R., 782
Domingues, A. L., 946
Donovan, R. M., 202
Dooley, S. W., 151
Dowling, A., 673
Drabick, J. J., 622
Drew, W. L., 570
Dubé, M., 157
Dubois, D. R., 1448
DuChateau, B. K., 115
Ducos, J., 1376
Dudley, J. P., 293
Duffy, L., 862
Duncan, I., 1100
Duncan, J., 517
Duncanson, F., 1394
Dunny, G. M., 1549
Eberhard, M. L., 403
Echevarria, J. E., 1300
Echevarria, J. M., 1300
Eckels, K. H., 1448
Edelman, C. K., 68
Edelman, R., 1448, 1508
Edwards, K. M., 476
Edwards, M. S., 88
Eh, J. P., 971
Eichinger, G., 1096
Eiffert, H., 122
Eizirik, D. L., 744
El-Awad, E.-H., 1037
Elias, A., 433
Elkin, E. P., 362
Elkins, W. R., 51
Elting, L. S., 1344
Embree, J. E., 1134
Emerson, S., 517
Emonyi, W., 1597
English, R. V., 543
Ennis, F. A., 27
Entenza, J. M., 100
Epstein, J. S., 748
Epstein, L., 286
Epstein, L. G., 1586
Erickson, R. L., 216
Ericsson, M., 110
Erlandsen, S. L., 1549
Erlinger, S., 433
Erttmann, K. D., 955
Erturk, M., 1100
Eslava, C., 1610
Esolen, L. M., S24
Espaze, E., 377
Espejo, L., 468
Esteban, E., 787
Esterlitz, J. R., 782
Estes, M. K., 34
Evans, L. A., 1141
Everett, V. D., 339
Ewald, J. H., 140
Ezzell, J., 1518
Faden, H., 862
Fahey, J. L., 1165
Federici, M. E., 1157
Feinberg, J., 165
Feldmann, H., 1456
Fenyö, E. M., 1367
Ferbas, J., 775
Ferrer, J. F., 787
Fessell, J., 673
Fiedler, B., 1616
Fife, K. H., 759
Fijen, C. A. P., 848
Fikrig, E., 500
Finley, R. W., 242
Fisher, P. E., 570
Fisher-Hoch, S. P., 527
Fitzgerald, M. A., 368, 461
Flanigan, T. P., 419
Flavell, R. A., 500
Fleisher, G. R., 630
Fleming, I., 1404
Flexner, C., 1394
Fluckiger, U., 100
Forsgren, M., 678
Fortier, A., 841
Fournier, J.-M., 701
Fraimow, H., 1539
Frame, P., 165
Franchini, G., 1353
Francot, G. J. M., 1483
Frasch, A. C. C., 1570
Fredeking, T., 834
Freedman, D. O., 927, 1054
Frey, T., 507
Friedlander, A., 1518
Friedman, J. M., 991
Fujita, M., 682
Fukunaga, M., 878
Fung, M. S. C., 1384
Furer, E., 834
Gabiano, C., 1000
Gage, K. L., 636
Gallay, P., 1319
Galli, L., 1000
Galloway, D. A., 1075
Gambino, G., 1637
Gan, Y.-J., 436
Ganes, D., 1394
Garcia, L. S., 494
Garcia, P., 396
García-Barbal, J., 1344
Garin, B., 1353
Garland, S. M., 1047
Garrett, K. F., 1557
Garrido, E., 396
Gary, H. E., Jr., 753, 986
Gasbarrini, G., 1042
Gaynes, R. P., 1622
Geheb, H., 189
Gellin, B. G., S1, S3
Gerber, M. A., 231
Gerberding, J. L., 1410
Gerding, D. N., 615
Gestas, P., 1304
Getachew, E., 841
Gianferante, L. E., 227
Gilchrist, S., 986
Gillespie, S. H., 713
Gillette, S. G., 1279

Giorgi, J. V., 775
Giorgio, C., 1539
Girard, P.-M., 653
Givner, L. B., 453
Glaser, J. B., 1007
Glass, R. I., 439
Glauser, M. P., 100, 1319
Glaziou, P., 247, 1304
Glutzer, E., 570
Godoy, N., 396
Gojobori, T., 1575
Goldbeck, C., 1110
Goldstein, S., 51
Gonzalez, P., 362
González Cappa, S. M., 1570
Gonzalez-Peralta, C., 962
Goodgame, R. W., 419
Gopinath, R., 258, 1630
Gordon, S. M., 573
Gorse, G. J., 782
Gowland, P. L., 1384
Graepel, P., 1384
Grafe, M. R., 1601
Graham, B. S., 429, 782
Graham, D. Y., 34
Graham, G. G., 1593
Gramenzi, A., 1042
Grandis, J. R., 729
Granger, D. L., 60
Gratacós, M. L., 1344
Graves, L. M., 693
Greaves, M. F., 44
Green, K. Y., 535
Green, M., 1539
Greenberg, D. P., 76
Greenberg, R., 449
Greenwood, B. M., 1316
Greer, C. E., 498, 1096
Greifinger, R. B., 151
Greipel, J., 1616
Griffin, D. E., S24
Grimm, L., 1606
Grob, P., 1384
Grohmann, G. S., 439
Grosset, J., 479
Grothues, D., 1616
Gruber, T., 1007
Guerrant, R. L., 494
Guillen, I., 1570
Günthard, H. F., 1384
Gutman, L. T., 339
Hachem, R., 384
Hack, C. E., 663
Hack, D. C., 1518
Hadley, W. K., 362, 578
Haghighat, D., 157, 238
Hakura, A., 682
Hall, C. B., 1586
Hall, H. E., 1432
Hall, M. A., 88
Hall, W. W., 206
Hamed, K. A., 1292
Hamilton, D. C., 1635
Hammill, H. A., 308
Hampton, T. J., 709
Hamšiková, E., 1424
Hancock, D. D., 253
Handelsman, E., 996
Handy, V., 759
Hansen, E. J., 867
Happ, C. M., 636
Harabuchi, Y., 862
Harding, P. A., 766
Harris, R. J., 1052
Hartard, C., 828
Hartshorn, K. L., 802
Haubrich, R. H., 238
Havlik, J. A., Jr., 573
Havlir, D. V., 157, 488, 1601
Hawdon, J., 918
Hayat, C. S., 419
Hayes, L. J., 709
Hayward, A. R., 522
Hazell, S. L., 686
He, Q., 705, 873
Heath, J. L., 795
Hedges, M., 686
Heesemann, J., 140
Helminen, M. E., 867
Henderson, D. A., 284
Hennessey, K., 293
Henrard, D. R., 194, 553
Hensel, M., 1597
Heredia, A., 748
Herrero, M., 669
Hesley, T., 510
Hessol, N. A., 198
Heumann, D., 1319
Hewlett, I. K., 748
Hickman, M. E., 88
Hildreth, S., 425
Hillier, S., 1597
Hinson, H. P., 476
Hirazowa, A., 198
Hirji, K., 775
Hirsch, M. S., 1361
Hirsch, V. M., 51
Hirschl, A. M., 473
Hjelle, B., 1013
Ho, G. Y. F., 1404, 1418
Ho, H.-N., 775
Ho, J. L., 413
Hofmannová, V., 1424
Hogerman, D., 425
Hoke, C. H., 27, 1448
Hol, C., 1613
Hollinger, F. B., 553
Holm, S. E., 585
Holmberg, S. D., 198
Holmes, A., 894
Holmes, K., 1532
Holmes, K. K., 1134, 1597
Holodniy, M., 673
Honda, T., 1049
Hone, D., 1508
Hong, S.-T., 1582
Hook, E. W., III, 1579
Hooper, C. J., 553
Hooton, T., 189
Hoover, D., 1579
Hoover, D. R., 1284
Hopewell, P. C., 362, 578
Horsburgh, C. R., Jr., 362, 573, 578
Hoskyn, J., 1597
Hostetter, M. K., 600
Hostoffer, R. W., 82
Hotez, P., 918
Hsieh, C.-Y., 498
Hsing, A. W., 498
Hu, P. J., 686
Hu, S., 457
Hu, S.-L., 782
Huang, T. W., 498
Huffman, J., 1463
Hughes, J. M., 263
Hughes, W. T., 906
Hughlett, C., 165
Huguet, M.-F., 1376
Hultin, L. E., 775
Hunter, C. A., 939, 1057
Hurren, L., 1141
Hwang, L.-Y., 1418
Hyman, T., 1518
Hynes, N. A., 51
Icenogle, J. P., 753
Inglis, S. C., 1100
Ingram, D. L., 339
Inoue, M., 682
Inouye, S., 439
Insel, R., 1586
Ioli, V., 510
Iqbal, M., 517
Jackson, J. B., 553
Jackson, S., 299
Jacobson, J. M., 743
Jacobson, M. A., 189, 1394
Jacobson, S., 334
Jaffe, H. S., 570
Janoff, E. N., 299
Jansen, A. M., 1093
Jarlier, V., 479
Jarvis, L. M., 1018
Jendis, J., 318
Jenkins, J. J., 7
Jenkins, M., 308
Jenkins, R. L., 644
Jennings, R., 1100
Jensen, G. L., 227
Jensen, J., 390, 900
Jiang, X., 34
Jiménez, M. A., 396
Jin, H., 1323
Johnson, B. J. B., 636
Johnson, C. M., 543
Johnson, D. R., 1346
Johnson, J. T., 729
Johnson, P. R., 51, 753
Johnson, W. D., Jr., 413
Johnston, W. W., 339
Jolley, P. T., 724
Joly, V., 1331
Jones, N., 44
Jones, T. C., 413
Jones-Carson, J., 180
Jónsdóttir, I., 592
Jónsson, S., 592
Joshi, B., 748
Junker, A. K., 991
Kahn, J. O., 1288
Kain, K. C., 258, 1626, 1630
Kaiser-UCLA Vaccine Study Group, 76
Kane, C., 488
Kao, J.-H., 1128
Kapikian, A. Z., 535
Kaplan, E. L., 1346
Kaplan, J. E., 206
Kapur, V., 1348
Karchmer, A. W., 615, 644
Karlsson, A., 1367
Karpas, A., 742
Karyotakis, N. C., 384
Kato, K., 1575
Katz, B. P., 759
Katz, M. H., 198
Katz, S. L., S1, S3
Katzenstein, D., 1044
Katzenstein, D. A., 1009
Kayhty, H., 449
Kazura, J. W., 1339
Keefer, M. C., 782
Kelen, G. D., 194
Keller, M., 1279
Kemper, C. A., 157, 488
Kennedy, N., 713
Kenner, J. R., 1518
Kenneth Rich, for Women and Infants Transmission Study Group, 996
Kermode, A. G., 334
Kessler, D., 206
Khabbaz, R. F., 206, 1636
Khan, N. C., 1157
Khyatti, M., 1439
Kijlstra, A., 663
Kilbourne, E. D., 1432
Kilburn, J. O., 151
Killeen, K. P., 1518
Killmar, J. T., 906
Kim, H. H., 1606
Kimball, H. R., 261
Kimball, K. T., 419
Kimoto, T., 439
Kind, C., 318
Kingsley, L. A., 1284
Kisyombe, G., 713
Kiviat, N., 1597
Kiyosawa, K., 1575
Klein, R. S., 1404
Kleiner, D. E., 325
Klesney-Tait, J., 867
Kline, M. W., 308
Kloczewiak, M., 1490
Klotman, P. E., 325
Kobayashi, J. M., 1606
Kohl, S., 308
Kohn, F. R., 1473
Kok, T., 1052
Kokka, R., 553

Kolbeck, P. C., 351
Komaroff, A. L., 1
Kopp, J. B., 325
Korvick, J. A., 189
Koyama, M., 682
Kozal, M. J., 1292
Kramer, F., 189
Krasinski, K., 1003
Krause, P. J., 231
Krause, R. M., 265
Krawietz, I., 955
Kreiss, J. K., 1134, 1597
Kresina, T. F., 733
Kriesel, J. D., 1046
Kroodsma, K. L., 1292
Krugman, S., 510
Krukovets, I., 82
Kruppa, T. F., 955
Krystofik, D., 862
Ksiazek, T. G., 1636
Kumwenda, N., 510
Kung, A. H. C., 1473
Kuo, C.-C., 464
Kuppermann, N., 630
Kurane, I., 27
Kuritzkes, D. R., 766
Kuye, O., 1394
Kwok, S., 553
Kyle, D. E., 1626, 1630
Kyo, S., 682
Lahesmaa, R., 978
Lai, M.-Y., 1128
Lalezari, J. P., 570
Lammie, P. J., 403
La Montagne, J. R., 263
Landers, D., 308
Landon, G. C., 720
Lane, N., 488
Latimer, J. L., 867
Lau, J. Y. N., 1575
Lauer, B., 1456
Laughlin, M. D., 242
Leach, C. T., 293
Leake, E. R., 1532
Leal, M., 1041
Lee, A., 686, 1157
Lee, B. L., 912
Lee, H., 1308
Lee, L. A., 128
Lee, S. F., 748
Leedom, J. M., 157, 165
Le Floch, R., 377
Legters, L. J., 517
Leguizamón, M. S., 1570
Leinonen, M., 220
Lelievre, H., 701
Letson, G. W., 251
Levander, O. A., 351
Level, R., 433
Levin, M. J., 522
Levine, M. M., 1508
Levis, W. R., 1007
Levy, J., 449
Levy, R., 449
Lew, J. F., 535
Lewis, L. L., 44
Lewis, W. D., 644
Li, H., 1157
Li, Y. L., 527
Li, Y. Y., 686
Liaw, K.-L., 498
Liaw, Y.-F., 358, 1582
Lieb, S., 689
Lim, D. J., 1532
Lim, L. C. L., 115
Lin, D.-Y., 358
Lin, H. J., 553
Lin, P.-F., 1157
Lin, P.-R., 1638
Lindberg, A. A., 1508
Liou, R.-S., 1384
Lissen, E., 1041
Little, R., 802
Litton, M. J., 939
Liu, J.-Y., 1638
Liu, M., 1165
Liu, Z., 293
Liu, Z. L., 527
Lloyd, G., 44
Loiselle, P., 1490
London, W. T., 51
Long, C., 1586
Looareesuwan, S., 1626
Love-Homan, L., 733
Lovrich, S. D., 115
Luckey, D., 766
Ludlam, C. A., 1018
Lujan-Trangay, A., 962
Luquiaud, P., 247
Lushbaugh, W. B., 242
Lüthy, R., 1384
Luxemburger, C., 971
Luyendijk, L., 663
Luzuriaga, K., 286
Luzzati, R., 644
Lyman, C. A., 1557
Lynch, M., 1566
Lyytikäinen, R., 873
Ma, Q. R., 527
Mabey, D. C. W., 709
MacDonald, K. L., 254
MacGregor, R., 1053
Maciel, A., 927
Maciver, I., 867
Madonna, A., 396
Madore, H. P., 34
Maeda, H., 1023
Mahanty, S., 946, 1339
Maia e Silva, M. C., 927
Maitha, G., 1134
Makristathis, A., 473
Malamud, D., 1053
Malawista, S. E., 890, 1027, 1312
Malik, I. A., 517
Maloney, B., 334
Maloney, E. K., 128
Manns, A., 334
Manos, M. M., 498, 1077, 1093, 1096
Mansueto, S., 1637
Marcellin, P., 433
Marchetti, G., 1349
Margolick, J. B., 775
Markoff, L. J., 1304
Markowitz, L. E., S32
Markowitz, N. P., 202
Marmion, B. P., 1052
Marshall, S. H., 1539
Marshall, W. F., III, 1027
Marsters, S. A., 1323
Martin, K. A., 991
Martin, P. M. V., 247
Martinot-Peignoux, M., 433
Maruo, K., 1023
Maserati, R., 1349
Mason, C. J., 216
Massougbodji, A., 955
Mastrandrea, S., 750
Masur, H., 165
Mathiesen, D., 1027
Matthews, T. J., 60, 782
Matuschka, F.-R., 122
Maupin, G. O., 636
McCarthy, J. S., 736
McCormack, W. M., 1308
McCormick, J. B., 527
McCracken, G. H., Jr., 867
McCutchan, J. A., 157, 238, 1601
McDonald, H. M., 724
McDonald, P. J., 724
McElrath, M. J., 782
McFarland, E. J., 766
McGowan, J. E., Jr., 573
McIntosh, K., 996
McIntyre, K., 1586
McLean, C. S., 1100
McNerney, R., 713
McOmish, F., 1018
McQuay, L. J., 553
McQueen, P., 1141
Medeiros, A. A., 1539
Medrano, F. J., 1041
Mekalanos, J. J., 278
Mekalanos, J. K., 1518
Meltzer, M., 841
Menezes, J., 1439
Merigan, T. C., 673, 1009, 1044, 1165, 1292
Mermel, L. A., 1539
Merrill, D. P., 1361
Merriweather, A., 1054
Mertsola, J., 705, 873
Metchock, B., 573
Middeldorp, J. M., 13
Miller, A. J., 720
Miller, G. J., 44
Miller, W., 510
Minekawa, Y., 439
Miner, D., 570
Minson, A. C., 1100
Mintz, E. D., 468
Mirabelli, L., 1630
Mirandola, P., 211
Miskovsky, E., 510
Mitchell, H. M., 686
Mitsuya, H., 325
Miwatani, T., 1049
Miyamoto, K., 878
Mizoguchi, N., 1575
Mizokami, M., 1575
Mizuno, Y., 1575
Mocciaro, C., 1637
Monroe, S. S., 439
Montefiori, D. C., 51, 429
Montenegro, S., 946
Montenieri, J., 636
Montgomery, R. R., 890
Moore, T., 1003
Moran, A. P., 135
Moreillon, P., 100
Moretta, L., 1296
Morris, S., 673
Morris, V. C., 351
Morzunov, S., 1013, 1456
Moulia-Pelat, J. P., 247
Moye, J., 996
Mukai, T., 746
Mulholland, E. K., 1316
Muller, J., 748
Multicenter AIDS Cohort Study Group, 775
Mulvaney, G. G., 339
Muñoz, A., 1284
Muñoz, N., 1093, 1424
Murcar, N., 1288
Murray, H. W., 659
Murray, M., 522
Musher, D. M., 720
Musser, J. M., 1348
Myers, L. E., 553
Nagelkerke, N. J. D., 1134
Nakao, M., 878
Nara, P. L., 553
Nascimento, C., 413
Nasisse, M., 543
Nassos, P. S., 362
Nathanson, M. H., 890
National Institutes of Health AIDS Vaccine Clinical Trials Network, 429, 782
National Nosocomial Infectious Surveillance System, The, 1622
Naumovitz, D. W., 227
Navas, S., 669
Ndinya-Achola, J. O., 313, 1134, 1597
Necula, A., 1043
Nedunchezian, D., 484
Neil, G. A., 733
Neill, M. A., 1606
Nelson, D. S., 630
Nelson, P., 543
Nerurkar, V. R., 1353
Newman, R. D., 494
Ng, P., 1110
Ngelangel, C., 1093
Ngowi, F. I., 713
Nguyen, N. L., 247
Nichol, S. T., 1013, 1456
Nichols, L., 165

Nielsen, H., 135
Nikkari, S., 873
Nishimune, Y., 1589
Nishimura, M., 334
Njoo, F. L., 663
Norgren, M., 585
Norrby-Teglund, A., 585
Nosten, F., 971
Novák, J., 1424
Novakoski, W. L., 216
Novati, S., 1349
Novitsky, T. J., 630
Noya G., O., 396
Nutman, T. B., 736, 962
Ocampo, C., 468
O'Donnell, J. J., 189
Ohlenbusch, A., 122
Oishi, I., 439
Okabe, M., 1589
Okuno, T., 746
Ölander, R.-M., 705
Olliaro, P., 1349
Olmsted, S. B., 1549
O'Loughlin, J. A., 724
O'Malley, P., 198
Ombette, J., 313
Ong, C.-K., 1077, 1086
Oosting, J., 663
Opal, S. M., 622
Opekun, A. R., 34
Orani, A., 1349
O'Rourke, S., 775
Orso, M., 1349
Osterhaus, A. D. M. E., 443, S42
Osterholm, M. T., 254
Ostroff, S. M., 362, 578
Ott, G., 1110
Ottesen, E. A., 736
Out, T. A., 848
Owen, W. F., Jr., 570
Oz, H. S., 906
Pabón, R., 396
Paetznick, V., 384
Palardy, J. E., 622
Palasanthiran, P., 1593
Palmer, P. S., 476
Pamba, H. O., 1134
Pannier, M., 377
Panozzo, M., 1148
Papania, M., 151
Pardo, M., 669
Pardridge, W. M., 563
Paris, M., 867
Park, L., 775
Parkinson, A. J., 368, 461
Parkinson, S. J., 1498
Parks, D. J., 368, 461
Paros, M., 253
Parsmyr, K., 1367
Partridge, S., 76
Pate, E., 334
Patick, A. K., 1157
Patton, D. F., 7
Patton, D. L., 464
Pau, C.-P., 1043
Pauksens, K., 585
Pedneault, L., 68
Peltz, G., 978
Penny, R., 1141
Pepin, J., 313
Pereira, M. L. D., 494
Persing, D. H., 1027, 1312
Petajan, J. P., 1046
Peterman, J. H., 299
Peterman, T. A., 689
Peters, C. J., 1013, 1456
Peters, H. V., 368
Peterson, P. K., 457
Peto, J., 1093
Petty, B. G., 1394
Petzelt, J., 468
Peutherer, J. F., 1018
Peyton, C. L., 1077, 1089, 1093
Phair, J. P., 775, 1284
Phelps, W. C., 339
Phillips, K., 1498
Piccione, E., 1637
Piesman, J., 636, 883
Pilaski, J., 1456
Pinner, R. W., 693
Piot, P., 1134
Pitt, J., 996
Pizzo, P. A., 325, 894, 1557
Plaeger-Marshall, S., 1279
Plichart, C., 247
Plikaytis, B. D., 693
Plourde, P. J., 313
Plummer, F. A., 313, 1134, 1597
Pocidalo, J.-J., 653
Poffenberger, K. L., 748
Poiesz, B. J., 1007
Poli, L., 1304
Pollack, H., 1003
Pollak, P. T., 1635
Polsky, B., 189, 1394
Pontisso, P., 1042
Powderly, W., 165, 1394
Poyart, C., 701
Prieto, W., 396
Prince, A. M., 743
Proctor, R. A., 1033
Prückl, P. M., 473
Puhr, N. D., 128
Purcell, R. H., 517
Que, J., 834
Quinn, T. C., 194, 1308, 1579
Quirinale, J., 748
Quiroga, J. A., 669
Raad, I. I., 720
Rabodonirina, M., 749
Rafiqui, A. R., 517
Ramachandran, R. V., 1009, 1044
Ramirez, B., 733
Rasheed, S., 553
Rasmussen, L., 673
Raziuddin, S., 1037
Reed, S. G., 413
Reeves, M. W., 693
Reeves, W. C., 753
Rehder, C. D., 1346
Rehg, J. E., 934
Reichelderfer, P., 553
Reingold, A. L., 362, 578
Reiss-Levy, E., 686
Remington, J. S., 939, 1057
Remington, M., 20
Revie, D. R., 1157
Rex, J. H., 384
Rey, C., 1041
Reyes, I., 396
Reynes, J., 1376
Ribeiro, R. C., 7
Rice, L. B., 1539
Richard, P., 377
Richet, H., 377
Richter, M., 473
Riedo, F. X., 693
Rihs, J. D., 729
Rijkers, G. T., 854
Rios, M., 206
Roberts, M. S., 644
Roberts, P. L., 1597
Robertson, P., 1593
Roche, C., 1304
Roche, P. W., 1326
Rodriguez, M., 468
Rohr, L. H., 351
Roilides, E., 894
Rollin, P. E., 1456, 1636
Rolston, K. V. I., 1344
Römling, U., 1616
Rompalo, A. M., 1579
Ronald, A. R., 313
Roord, J. J., 254
Rose, R. E., 1157
Rosenkaimer, F., 659
Rota, J. S., S15
Rota, P. A., 795, S15
Roth, Z., 1424
Rotondo, G., 1637
Rotter, M. L., 473
Rowe, B., 1610
Rubino, S., 750
Rüdiger, H., 140
Ruo, S. L., 527, 1456
Rusconi, S., 1361
Russo, D., 413
Russomando, G., 1570
Ruta, S.-M., 1043
Rutledge, B. J., 1027
Ruuskanen, O., 705
Ruzek, M., 600
Ryan, R. W., 231
Rys, P. N., 1027
Sack, R. B., 256
Sadoff, J. C., 834, 1518
Safrin, S., 570, 912
Saint-Julien, L., 1331
Sakanari, J., 918
Sakata, Y., 1023
Saladino, R. A., 630
Samadpour, M., 1606
Samanta, H., 1157
Samore, M. H., 615, 644
Sande, M. A., 912
Sanders, L. A. M., 854
Sandman, L. A., 510
Sandström, E., 1367
Sandström, G., 110
Santona, A., 750
Sarai, A., 484
Saravolatz, L. D., 202
Sarjadi, 1093
Saruni, A. O. S., 713
Sathe, S. S., 484
Sato, K., 1023
Sato, M., 1049
Sattler, F., 630
Sattler, F. R., 165
Scaglia, M., 1349
Schachter, J., 1308
Schaffner, A., 745
Scharein, E., 828
Scheld, W. M., 254
Schell, R. F., 115, 499
Schiffman, M. H., 498, 1096
Schlesinger, M., 449
Schmid, D. S., 753
Schnabel, K., 1586
Schneemann, M., 745
Schoedon, G., 745
Schoenknecht, F. D., 1606
Schüpbach, J., 318, 1384
Schütze, K., 473
Schwartz, D. H., 782
Scollen, N., 44
Scotland, S. M., 1610
Sears, C. L., 494
Secchiero, P., 211
Secka, O., 1316
Seger, R., 318
Sei, S., 325
Seminario, L., 468
Serre, A., 1376
Shafritz, D. A., 1418
Shah, K., 1424
Shaio, M.-F., 811, 1638
Shanafelt, M.-C., 978
Shapiro, E. D., 231
Shaw, G. M., 194
Shearer, G. M., 334
Shearer, W. T., 308
Sheen, I.-S., 358
Shelton, B., 165
Shepard, D. S., S56
Sher, A., 946
Sheu, J.-C., 1128
Shi, Q., 351
Shi, X., 686
Siber, G. R., 630
Siddons, C. A., 251
Sifontes, R., 396
Silva, T. M. J., 494
Simmonds, P., 1018
Simmons, S. S., 1050
Simon, E. M., 362, 578
Simonpoli, A.-M., 653
Sinangil, F., 1288
Sison, J. P., 157

Sixbey, J. W., 7, 436
Sjogren, M. H., 1518
Sjöstedt, A., 110
Sköldenberg, B., 678
Skowron, G., 1165
Smereck, S. M., 202
Smit, F. T., 1483
Smith, A. L., 453
Smith, G. E., 782
Smith, H. R., 1610
Smith, P. D., 299
Smoak, B. L., 216
Sobel, J. D., 1566
Sodeyama, T., 1575
Song, K.-J., 1353
Soper, J., 339
Sougakoff, W., 479
Spaan, W. J. M., 13
Speert, D. P., 1524
Spielman, A., 122, 1027
Spiropoulou, C. F., 1013
Spruance, S. L., 1046
St. Claire, K. K., 339
Stablein, D. M., 782
Stamm, W. E., 1308
Stanberry, L., 1110
Steel, C., 962
Stefanescu, I., 1439
Steigbigel, R. T., 165
Steimer, K. S., 1288
Steinman, L., 978
Stevens, D. A., 173
Stevens, D. L., 609, 1463
Stewart, A.-C., 1093
Stewart, J., 1053
Stiehm, E. R., 1279
Stilma, J. S., 663
Stine, S. E., 439
Stone, E. N., 362, 578
Straley, S., 841
Strannegård, Ö., 678
Straus, S. E., 1
Streater, M., 227
Stromatt, S., 1046
Suara, R. O., 1316
Sullivan, J. L., 436
Summers, P. L., 1448
Sun, M., 425
Sundar, S., 659
Sundstrom, P., 390
Supromajakr, P., 746
Suzuki, K., 1575
Sviat, S. L., 636
Sweet, R. L., 500
Swerdlow, D. L., 468
Swiss Neonatal HIV Study Group, 318
Sztein, M. B., 1508
Tabrizi, S. N., 1047
Tacket, C. O., 1448, 1508
Talarico, C. L., 68
Tamin, A., 795
Tanaka, T., 34
Tang, Y. W., 527
Taniguchi, T., 1049
Tanizawa, O., 682
Tao, H., 500
Tao, P.-Z., 1003
Tardei, G., 1043
Tarkowski, A., 94
Tärnvik, A., 110
Tarr, P. I., 253, 1606
Tauxe, R. V., 128, 468
Taylor, D. N., 1518
Taylor, E., 1636
Taylor, R., 622
Tedder, R. S., 44
Teixeira, K., 946
Tejada, E., 468
Telford, S. R., III, 500, 1027
Temahivong, T., 258
Temmerman, M., 1134
Tenover, F., 1068
ter Kuile, F. O., 971
Teyssie, A. R., 1093
Thiele, D., 223
Thomas, D. L., 1579
Thomas, E. E., 991
Thomas, K., 299
Thompson, C. M., 630
Thompson, K., 1463
Thompson, S. E., III, 573
Thorisdottir, A. S., 1539
Tibaldi, C., 1000
Ticehurst, J., 517
Tidwell, B. H., 242
Tilles, J. G., 157, 238
Tindall, B., 1141
Tiwari, J., 717
Tobias, P. S., 1319
Tomasik, Z., 318
Tompkins, L. S., 1068
Tompkins, M. B., 543
Tompkins, W. A., 543
Tonawanda/Williamsville Pediatrics, 862
Tong, Z., 527
Török, T. J., 986
Torres, Y., 1041
Torrez-Martinez, N., 1013
Torriani, F. J., 1601
Torroella, M., 1093
Tovo, P.-A., 1000
Trepo, C., 749
Trethewey, P., 20
Triccas, J. A., 1326
Trimble, J., 1157
Tristram, D. A., 425
Trofa, A., 1518
Trollfors, B., 220
Truffot-Pernot, C., 479
Tsai, S.-L., 1582
Tsai, T. F., 251
Tsang, M. L., 1141
Tsarev, S. A., 517
Tsigler, D., 484
Tümmler, B., 1616
Tyndall, M., 313
Uchiyama, T., 334
Uhrin, M., 500
Unnasch, T. R., 1054
Urbáez, J. D., 396
Utagawa, E., 439
UytdeHaag, F. G. C. M., 443
Uzzau, S., 750
Vadheim, C. M., 76, 717
Vahey, M., 553
Vaishampayan, J., 1566
Valdesuso, J., 535
Valdimarsson, H., 592
Valway, S. E., 151
Van Allen, M. I., 991
van Amerongen, G., 443
van Binnendijk, R. S., 443, S42
van der Heijden, R. W. J., 443
van der Horst, C., 165, 189, 1394
van de Winkel, J. G. J., 848, 854
van Dijk, H., 1613
Van Dijke, E. M., 1613
van Dissel, J. T., 234
van Furth, R., 234
van Grunsven, W. M. J., 13
van Langevelde, P., 1033
Van Nest, G., 1110
Van Voorhis, W. C., 1334
van Zanten, S. J. O. V., 1635
van Zwet, Th. L., 234
Vandepitte, J., 701
VanderZanden, L., 636
Vanijanonta, S., 1626
Vann, J. M., 1033
Vaughn, D. W., 27, 1448
Vázquez, J. A., 696
Vazquez, J. A., 1566
Vazquez-Torres, A., 180
Veglia, F., 1000
Vendrell, J.-P., 1376
Venzon, D., 894
Verduin, C. M., 1613
Verhoef, J., 1613
Vermund, S. H., 1284, 1404
Vickers, R. M., 729
Vierucci, A., 1000
Vigneswaran, R., 724
Viljanen, M. K., 705, 873
Villa, L. L., 1077, 1086
Viscarello, R. R., 308
Visscher, B. R., 293
Vitale, G., 1637
Vittinghoff, E., 578
Viðarsson, G., 592
Vlahov, D., 1636
von der Hardt, H., 1616
von Wulffen, H., 828
Vonka, V., 1424
Voorhorst-Ogink, M. M., 854
Wabinga, H. R., 1093
Wahl, S. M., 299
Wahlquist, S. P., 494
Wainwright, N., 1490
Waldman, J., 1096
Waldman, S. A., 1498
Waldor, M. K., 278
Walker, J. D., 189
Wallace, L. A., 1300
Walsh, E. E., 345
Walsh, T. J., 894, 1557
Walter, E. B., 1050
Wang, T.-H., 1128
Wang, Z.-D., 795
Wara, D., 308
Ward, B. J., S24
Ward, J. I., 76
Ward, M. E., 709
Warner, T., 900
Warren, H. S., 1490
Wasi, C., 746
Wasi, S., 1120
Wasilauskas, B. L., 453
Wasserman, S. S., 1448, 1508
Watson, H. G., 1018
Weaver, R. E., 693
Webster, H. K., 1626
Wedner, H. J., 1
Weening, R. S., 848
Weinberg, J. B., 60
Weiss, S. H., 748
Weiss, W., 165
Welliver, R. C., 425
Wells, C. L., 1549
West, D., 510
Wheeler, C. M., 1077, 1089, 1093, 1096
White, A. C., Jr., 419
White, C. J., 522
White, M. R., 802
White, N. J., 971
Whittam, T. S., 1348
Whittle, H. C., 709
Wiesenfeld, H. C., 500
Wiktor, S. Z., 334
Wilfert, C. M., 286
Willerford, D. M., 1597
Williams, J., 841
Williams, M. E., 946
Williams-Herman, D., 308
Williamson, J., 1052
Willinger, B., 473
Willshaw, G. A., 1610
Wilson, C., 286
Wilson, P., 20
Wilson, S., 713
Winters, M. A., 553, 1292
Wirtz, R. A., 883
Wisnewski, A., 733
Wolf, J., 862
Wolitz, R., 673
Wongsrichanalai, C., 258, 1626, 1630
Wood, R., 1009
Woodley, C., 151
Woodman, R. C., 1524
Woodrow, C., 971
Woods, C. R., 453
Wright, P. F., 782
Wroten, J. E., 689
Wuhib, T., 494
Wurm, F. M., 1323
Wynn, T. A., 946
Wynne, D., 1288

Xu, X., 1432
Xu, Z. Y., 527
Yacobi, A., 1394
Yajko, D. M., 362, 578
Yamamoto, K., 1049
Yamamoto, T., 746
Yamanaka, N., 862
Yamanishi, K., 746
Yamazaki, K., 439
Yamazaki, S., 439
Yan, S., 609
Yanagihara, R., 1353
Yang, J., 563
Yang, K. D., 1638
Yang, P.-M., 1128
Yang, R., 1323
Yang, Z.-P., 464
Yangco, B., 157
Yao, Y., 157
Yarchoan, R., 325
Yau, Y., 258
Ye, K. L., 527
Yeh, C.-T., 1582
Yeni, P., 1331
Yen-Lieberman, B., 553
Yoksan, S., 27
You, S.-L., 498
Young, R. K., 766
Yu, V. L., 729
Zack, P. M., 51
Zaidi, A. A., 689
Zamarchi, R., 1148
Zandomeni, R. O., 787
Zea-Flores, G., 962
Zegers, B. J. M., 854
Zenilman, J., 1579
Zerbe, G. O., 522
Zerpa, N., 396
Zervos, M. J., 1539, 1566
Zhan, M. X., 1003
Zhang, T., 498
Zhang, T. Y., 1096
Zhou, J. T., 429
Zhou, J. Y., 429
Ziegler, J. B., 1593

Subject Index

Acyclovir, VZV resistance, 68
Aggregation substance, plasmid-encoded *E. faecalis* surface protein, 1549
AIDS (*See* Human immunodeficiency virus type 1 infection)
Alovudine, anti-HIV activity, concentration-controlled trials, 1394
Amoxicillin, use in contaminated head and neck surgery, 729
Amphotericin B, and IFN-γ, for *C. neoformans* infection, mouse model, 1331
Ancylostoma caninum, hyaluronidases, role in pathogenesis, 918
Animal model
  B. burgdorferi, DNA, in tissue after treatment, mouse, 1312
  C. albicans
    immune responses to enolase, mouse, 390
    infection, disseminated, host resistance, macrophage role in, 900
    macrophage killing in normal and immunodeficient mice, 180
  C. burnetii, disseminated infection, endocarditis in, immunocompromised mice, 223
  C. parvum, infection, paromomycin vs. aminoglycosides and azithromycin for, immunosuppressed rat, 934
  C. pneumoniae, pneumonitis, lung ultrastructure, mouse, 464
  coxsackievirus B3, virulence, selenium-deficient mouse, 351
  E. coli, enterotoxin, heat-stabile, intestinal kinetics, suckling mouse, 1498
  E. coli J5 LPS-specific IgG, effect against sepsis, neutropenic rat, 622
  feline immunodeficiency virus, clinical disease, 543
  F. tularensis, rifampicin-resistant, virulence, mouse, 841
  H. influenzae, nontypeable, otitis media, chinchilla, 1532
  HSV-2 vaccine
    adjuvant influence, 1110
    using mutant type, 1100
  influenza, heterotypic immunity, mouse, 1195
  L. monocytogenes growth, after TNF injection, mouse, 234
  lymphocytic choriomeningitis, superantigen shock, mouse, 1189
  M. catarrhalis, induced penicillin neutralization, in pneumococcal pneumonia, mouse, 1613
  measles, replication and immunity, macaque, 443
  P. carinii, evaluation of 10 drugs against, rat, 906
  sepsis
    E. coli, endotoxin-neutralizing protein vs. MAb for, 630
    effect of bactericidal/permeability increasing protein, mouse, 1473
  T. gondii
    encephalitis, cytokines in lymph nodes and brain, mouse, 939
    and *P. carinii* infections, combined prophylaxis, mouse, 653
Anisakis simplex, hyaluronidases, role in pathogenesis, 918
Antibody to
  B. burgdorferi, to diagnose Lyme disease, 499, 500
  B. pertussis hemagglutinin, protection in schoolchildren, 705
  CMV, in HIV-infected patients at risk for retinitis, 673
  HCV, 669
  H. influenzae and *M. catarrhalis*, to diagnose cause of pneumonia, 220
  HIV-1
    neutralizing, after seroconversion, 1141
    from PBMC, relation to disease progression, 1376
    transplacental, decay in neonates and infants, 1593
  HSV-2, cervical, 20
  M. catarrhalis
    antigenically conserved protein, 867
    and *H. influenzae*, to diagnose cause of pneumonia, 220
  O. volvulus, 955
  S. pneumoniae polysaccharides, 592
  T. cruzi, *trans*-sialidase, 1570
  TNF, effect on granulocyte and monocyte flux into inflammatory exudate, mouse model, 234
Antibody-dependent cellular cytotoxicity antibody
  in EBV-positive patients, 1439
  to HIV-1 at birth, titers, 308
Antigen, filarial, proliferative and IL-10 responses to, 403
Antimicrobials, oral, over-the-counter availability, 1256
Antimony, plus IFN-γ, for visceral leishmaniasis, 659
Artesunate-mefloquine, for multidrug resistant *P. falciparum*, 971
Arthritis, human inflammatory, pathogenesis, 978
Arthritogenicity, *S. aureus*, TSST-1 effect, 94
Aspergillus, invasive infection, in orthotopic liver transplantation, risk factors, 644
Aspergillus fumigatus, effect of GM-CSF and IFN-γ on PMNL activity, 894
Astrovirus, gastroenteritis, outbreak, in Japan, 439
Azithromycin, for *C. parvum* infection, immunosuppressed rat model, 934

Babesiosis, and Lyme disease, acquisition, risk from blood transfusion, 231
Bacille Calmette-Guérin, immunization, healthy adults, 476
Bacteremia
  M. avium complex, in AIDS, treatment, 157, 578
  vancomycin vs. teicoplanin for, in cancer, 1344
Bactericidal/permeability increasing protein
  effect on gram-negative sepsis, mouse model, 1473
  MAb characterization, 1483
Bellagio consensus, children's vaccine initiative report, S63
Bordetella pertussis
  hemagglutinin, antibody and protection in schoolchildren, 705
  infection, outcome in immunized population, 873
Borrelia, spirochetes, enzootic transmission, in Japan, 878
Borrelia burgdorferi
  antibody, for diagnosis, 499, 500
  arthritis, reactive, 978
  DNA
    detection in museum specimens, 1027
    in tissue after treatment, mouse model, 1312
  enzootic cycle, in Colorado, 636
  Fc receptor and non–Fc receptor–mediated phagocytosis, 890
  OspA in *I. scapularis*, changes in level during life cycle, 883
  spirochetes, seroprotective groups, 115
  transmission, role of dormice, 122
Boutonneuse fever, IFN-γ levels, 1637
Bovine leukemia virus, expression, role of host soluble factors, 787
Branched DNA signal amplification, to monitor HIV-1 burden, 1172
Brucella melitensis, transmission, foodborne trend, 1216
Burn, infection, *P. aeruginosa*, ceftazidime for, 377

Calciviruses, genetic polymorphism, 535
Campylobacter jejuni, seroreactivity and gangliosides, Guillain-Barré syndrome, 828
Cancer, cervical, HPV-16 antibody in, 1424
Candida
  antifungals, in vivo and in vitro activity, 384
  in dental plaque, in AIDS, 1053
  invasive infection, in orthotopic liver transplantation, risk factors, 644
Candida albicans
  immune responses to enolase, mouse model, 390
  infection, disseminated, host resistance, macrophage role in, 900
  macrophage killing in normal and immunodeficient mice, 180
  in recurrent vulvovaginal candidiasis, karyotyping, 1566

Carcinoma, thymic, EBV in, 7
Ceftazidime
for *P. aeruginosa* burn infection, 377
resistance, among nosocomial gram-negative bacilli, in US, 1622
Central nervous system CMV infection
diagnosis, rapid, in AIDS, 1275
in vitro neuronal model, 1267
Chagas' disease, *trans*-sialidase, antibodies to, 1570
Chlamydia pneumoniae, pneumonitis, lung ultrastructure, mouse model, 464
Chlamydia trachomatis infection
EIA, culture, and PCR for diagnosis, 500
ocular, PCR for detection, 709
urethral, diagnosis by ligase chain reaction assay, 1308
Chloroquine, for falciparum malaria, 258
Cholera vaccine workshop, October 1993, 256
Chronic fatigue syndrome, IDSA meeting presentation, 1
Chronic granulomatous disease, *P. cepacia* infection, nonoxidative killing, 1524
Ciliary neurotrophic factor, and herpes labialis, 1046
Clindamycin, use in contaminated head and neck surgery, 729
Clinical microbiology laboratory, new technology, 1068
Clostridium difficile
diversity, in tertiary referral hospital, 615
stool cytoxin b, risk factors and role of sucralfate, 227
Colonization factor antigen III, *E. coli*, 1049
Condyloma acuminatum, pediatric, 339
Contaminated head and neck surgery, antibiotic efficacy, 729
Coxiella burnetii, disseminated infection, endocarditis in, in immunocompromised mice, 223
Coxsackievirus B3, virulence, selenium-deficient mouse model, 351
C-reactive protein, effect of ivermectin on, in onchocerciasis, 663
Cryptococcus, meningitis, in AIDS, fluconazole for, 239
Cryptococcus neoformans
infection, IFN-γ and amphotericin B for, mouse model, 1331
killing, by macrophages and fluconazole, 173
Cryptosporidium, in AIDS, paromomycin for, 749
Cryptosporidium parvum diarrhea
in Brazil, 494
paromomycin for, 419, 1349
Cystic fibrosis, epidemiology of *P. aeruginosa* chronic infection, 1616
Cytomegalovirus
antibody, in HIV infection, 673
DNA, detection in serum, correlation with CMV retinitis, in AIDS, 1271
HIV, HBV, and HCV, risk in health care workers, 1410
infection
CNS, rapid diagnosis, in AIDS, 1275
in HIV infection, molecular epidemiology and disease progression, 293
after organ transplantation, IE mRNA in, 1264
retinitis, in AIDS, treatment, ACTG trial, 189
pathogenesis, interaction with platelets and glycoproteins, 1120
replication, promotion by differentiation, 1267
Cytotoxic T lymphocyte activity, HIV-1–specific, in children born to infected mothers, 1296

Dengue virus
hemorrhagic fever, reactivation of HHV-6, in children, 746
IL-1 production by human monocytes, 811
infection, plasminogen cross-reactive antibodies and hemorrhage, correlation, 1304
vaccine
candidate, immunogenicity, 1448
live attenuated, T cell responses, 27
3′-deoxy-3′-fluorothymidine, anti-HIV activity, concentration-controlled trials, 1394
Desferrioxamine B, role in PMNL killing of *Y. enterocolitica*, 140
Diarrhea
C. parvum, in AIDS, paromomycin for, 419, 1349
Norwalk virus, 34
parasitic etiology, in HIV infection, in Brazil, 494
Didanosine, for HIV-1 infection, MT-2 cell tropism as marker for treatment response, 1367
Dideoxycytidine, for HIV-1 infection, effect on immune activation, 1165
DNA
analysis, macrorestriction, to type *H. pylori* in gastritis, 473
EBV, during mononucleosis, 436
HHV-6, detection, in lymphoproliferative disorders, 211
HIV, decrease after nucleoside therapy, 202

Editorial, papillomavirus, 1075
Encephalitis
HSV, cytokines and other markers of immune response, 678
T. gondii, cytokines in lymph nodes and brain, mouse model, 939
Endocarditis
associated with *C. burnetii* disseminated infection, in immunocompromised mice, 223
S. epidermidis, methicillin-resistant, treatment, 100
Enolase, *C. albicans*, immune response, mouse model, 390
Enterococcus, insertion sequences, clonal relationship, 1539
Enterococcus faecalis, enterocyte endocytosis, 1549
Enterotoxin, *E. coli*, heat-stabile, intestinal kinetics, suckling mouse, 1498
Endotoxic shock, treatment, 1490
Enzyme immunoassay, to diagnose *C. trachomatis* infection, 500
Epidemiology
astrovirus, gastroenteritis, outbreak, in Japan, 439
babesiosis, and Lyme disease, acquisition, risk from blood transfusion, 231
B. burgdorferi, transmission, role of dormice, 122
B. melitensis, transmission, shift toward foodborne, 1216
Borrelia spirochetes, enzootic transmission, in Japan, 878
B. pertussis, infection, outcome in immunized population, 873
C. difficile
diversity in tertiary referral hospital, 615
stool cytoxin b, risk factors and role of sucralfate, 227
CMV, HIV, HBV, and HCV, risk in health care workers, 1410
C. parvum, diarrhea, in HIV infection, in Brazil, 494
diarrhea, parasitic etiology, in HIV infection, in Brazil, 494
E. coli O157, strain comparison in cattle and humans, 251, 253
E. coli O157:H7, antibiotic-resistant, in Washington State, 1984–1991, 1606
filariasis, lymphatic, antibody responses, in children, 1339
GAS serotypes, changes from pharyngitis, 1346
gastroenteritis, astrovirus, outbreak, in Japan, 439
GBS, carriage in pregnant mothers and infants, in Gambia, 1316
gram-negative bacilli, ceftazidime resistance, in US, 1622
hantavirus, transmission, rat model, 1589
HBV infection, HIV, HCV, and CMV, risk in health care workers, 1410
HCV infection
HBV, HIV, and CMV, risk in health care workers, 1410
transmission, via needlestick, confirmation by molecular analysis, 1575
HEV infection, epidemic, in Pakistan, 517
HFRS in China, retrospective and prospective analysis, 527
HIV-1 infection
at-risk women, risk for HPV infection, 1404

genotype, serologic significance for epidemic, 1043
HBV, HCV, and CMV, risk in health care workers, 1410
incidence in homosexual men, CD4 cell count *100/mm*^{3}, 1284
opportunistic infections and malignancies, trends, 198
pediatric dentist, look-back investigation follow-up, 254
prevalence and correlates of cervical HIV-1 DNA, 1597
progression in mother-child pairs, 1000
risk in women with genital ulcers, 313
transmission, 308, 1134
unsuspected, in seronegative emergency patients, 194
vertically acquired, in children, 766, 996
viral load, in vertically infected infants, 1279
HPV
infection, genital, risk factors, 753
novel sequences, 1086, 1089, 1096
H. pylori
cohort effect, 1634, 1635
transmission, communitywide, 686
HTLV-I
genotyping, by PCR, viral evolution and dissemination, 1353
transmission, insect, 44
HTLV-I and -II, and HIV-1, infections, prevalence in Hansen's disease, 1007
HTLV-II, transmission in HTLV-I–screened blood products, 206
infectious diseases, emergence, 263, 265, 272, 278, 284
L. monocytogenes, outbreak, 693
Lyme disease
and babesiosis, acquisition, risk from blood transfusion, 231
transmission, role of dormice, 122
M. avium complex, infection, in HIV infection, environmental risk factors, 362
malaria, acquisition, reducing risk in travelers, 257
measles virus infection
control programs, S32
susceptibility, in young American adults, 216
O. volvulus infection in
endemic and nonendemic populations, 736
hyperendemic areas, 1054
P. aeruginosa infection
chronic, in cystic fibrosis, 1616
outbreak, in burn unit, multiply resistant strains, 377
RSV, surveillance, 1985–1990, in US, 986
S. pneumoniae infection
invasive, in Alaska, 368
serotypes and resistance, in Alaska, 461
Salmonella infection, antimicrobial-resistant, incidence in US, 128
Seoul hantavirus, seropositivity, among IDUs, 1636
tuberculosis, multidrug-resistant, in New York prison system, 151
V. cholerae, infection, severe, association with blood group O in Peru, 468
Epstein-Barr virus
capsid protein, immunodominant domains, 13
infection, gp350 antibodies and ADCC responses, 1439
mononucleosis, DNA in serum, 436
Epstein-Barr virus–associated carcinoma, 7
Errata
Anaissie et al., 1994;170:383, 1641
Cambau et al., 1994;170:479–83, 1351
Yarchoan et al., 1994;169:9–17, 260
Escherichia coli
enterotoxigenic, CFA/III, 1049
enterotoxin, heat-stabile, intestinal kinetics, mouse model, 1498
J5 LPS-specific IgG, effect against sepsis, neutropenic rat model, 622
O157, strain comparison in cattle and humans, 251, 253
O157:H7, antibiotic-resistant, in Washington State, 1984–1991, 1606
O44:H18, enteroaggregative isolates, 1610
sepsis, endotoxin-neutralizing protein vs. MAb for, 630
vaccine, polyvalent, safety and immunogenicity, 834

Falciparum malaria, chloroquine for, 258
Fc receptor, role in *B. burgdorferi* phagocytosis, 890
Fcγ receptor
phenotype distribution, in children with respiratory tract infection, 854
polymorphism, in children with septic shock, 848
Feline immunodeficiency virus, clinical disease, cat model, 543
Filariasis
antigens, proliferative and IL-10 responses to, 403
lymphatic, antibody responses, in children, 1339
W. bancrofti, Og4C3 antigen, marker of infection and worm burden, 247
Fluconazole for *C. neoformans*
infection, 173
meningitis, high-dose, in AIDS, 239
Fluoroquinolone, resistance, in *M. tuberculosis* mutant, 479
Foscarnet, and ganciclovir, for CMV retinitis, in AIDS, treatment, ACTG trial, 189
Francisella tularensis
immunity after natural infection, 110
rifampicin-resistant, virulence, mouse model, 841

Ganciclovir, and foscarnet, for CMV retinitis, in AIDS, treatment, ACTG trial, 189
Gastritis, *H. pylori*, single and multiple strain colonization, detection by DNA analysis, 473
Gastroenteritis, astrovirus, outbreak, in Japan, 439
Genital herpes
immunity, local, 20
vaccine
adjuvant influence, 1110
using mutant type, 1100
Gonorrhea. *See Treponema pallidum* infection
Gram-negative bacilli, ceftazidime resistance, in US, 1622
Granulocyte-macrophage colony-stimulating factor
effect on PMNL activity against *A. fumigatus*, 894
for visceral leishmaniasis, 413
Group A streptococci
mitogen, proliferative response of PBMC, 585
serotypes, changes from pharyngitis, 1346
Group B streptococci
carriage in pregnant mothers and infants, in Gambia, 1316
neutrophil killing, 88
Guillain-Barré syndrome, *C. jejuni* seroreactivity and gangliosides in, 828

Haemophilus influenzae
and *M. catarrhalis*, pneumonia, diagnosis by serology, 220
nontypeable
nasopharyngeal colonization and otitis media, 862
otitis media, chinchilla model, 1532
type b
peptidoglycan, effect on meningeal inflammation and blood-brain barrier permeability, 254
vaccine, conjugate, 76, 1050
Hantavirus
pulmonary syndrome, detection of Muerto Canyon virus RNA, 1013
Seoul, seropositivity, among IDUs, 1636
transmission, rat model, 1589
Hawaii virus, molecular characterization, genetic polymorphism among calciviruses, 535

Helicobacter pylori
cohort effect, 1634, 1635
gastritis, single and multiple strain colonization, detection by DNA analysis, 473
LPS, neutrophil activation by, 135
transmission, communitywide, 686
Hemorrhagic fever with renal syndrome
retrospective and prospective analysis, in China, 527
severe, due to Puumala virus, new strain, 1456
Hepatitis B virus
envelope variants, molecular characterization, 1300
HCV, and HDV, infection, double and triple, absence of precore stop mutant, 1582
infection
chronic, spontaneous HBsAg clearance, role of HCV superinfection, 358
HIV, HCV, and CMV, risk in health care workers, 1410
perinatal, role of maternal virus load, 1418
vaccine, effect of age on immunogenicity, 510
Hepatitis C virus
false-positive syphilis tests, association with, 1579
HBV, and HDV infection, double and triple, absence of precore stop mutant, 1582
and HDV, influence on chronic HBsAg carrier state, 358
infection
chronic, IgM antibody to HCV, HCV replication, and liver disease, 669
HBV, HIV, and CMV, risk in health care workers, 1410
mixed, in chronic hepatitis C, 1128
reinfection and reactivation, in multitransfused hemophiliacs, 1018
transmission, via needlestick, confirmation by molecular analysis, 1575
type 1, familial cluster, 1042
Hepatitis delta virus, HCV, and HBV, infection, double and triple, absence of precore stop mutant, 1582
Hepatitis E virus, infection, epidemic, patterns of response, 517
Herpes labialis, association with ciliary neurotrophic factor, 1046
Herpes simplex virus
encephalitis, cytokines and other markers of immune response, 678
infection, acyclovir-resistant, in AIDS, HPMPC for, 570
type 2
local immunity, 20
vaccine, adjuvant influence, 1110
Human herpesvirus 6
neuroinvasion and persistence, in children, 1586
in peripheral lymphocytes and lymphoproliferative disorders, 211
reactivation, in children with dengue hemorrhagic fever, 746
Human immunodeficiency virus type 1
ADCC antibody titers at birth, 308
antibody
neutralizing, after seroconversion, 1141
synthesis, in vitro, 1003
transplacental, decay in neonates and infants, 1593
anticryptococcal activity, of infected monocytes, 60
DNA
cervical inflammation and shedding, 1597
decrease after nucleoside therapy, 202
immune complex formation, 429
infection
advanced, treatment, 742, 743
alovudine for, 1394
antibody secretion, relation to disease progression, 1376
at-risk women, risk for cervical intraepithelial lesions, 1404
bDNA, to monitor viral burden, 1172
Candida in dental plaque, 1053
$CD8^+$ cell activation, 775
CMV antibody response, 673
CMV infection in, 189, 293, 1271, 1275
C. parvum diarrhea in, paromomycin for, 419, 1349
Cryptococcus, meningitis, in AIDS, fluconazole for, 239
Cryptosporidium infection, paromomycin for, 749
and disseminated MAC infection, predictors of survival, 573
genotype, serologic significance for epidemic, 1043
genotypic and phenotypic analysis, after prolonged stavudine therapy, 1157
HBV, HCV, and CMV, risk in health care workers, 1410
and HSV infection, acyclovir-resistant, treatment, 570
and HTLV-I and -II, infections, prevalence in Hansen's disease, 1007
IL-2 effects on CD4 cell counts, 1044
incidence in homosexual men, CD4 cell count *100/mm*^{3}, 1284
in infants, 318, 1279
intestinal immunoglobulins, 299
MAC bacteremia in, 157, 362, 484, 488, 1601
MT-2 cell tropism, marker of treatment response, 1367
opportunistic infections and malignancies, trends, 198
pathogenesis, IDSA presentation, 286
PCP in, treatment, 165, 912
progression in mother-child pairs, 1000
risk in women with genital ulcers, 313
transmission, vertical, 308, 1134
unsuspected, in seronegative emergency patients, 194
vertically acquired, in children, 766, 996
virus load, 325, 1009
and VZV infection, acyclovir-resistant, 68
zidovudine for, B and T cell function, 1148
zidovudine– and dideoxycytidine–induced immune activation, 1165
MAb to gp120 V3 loop, phase I/II study, 1384
P. aeruginosa exotoxin for, 1180
pol gene, detection of resistance mutations, 1292
replication, inhibition by therapy, in monocytes/macrophages, 1361
RNA, quantification methods, 553
specific CTL activity, in children born to infected mothers, 1296
syncytium-inducing, effect of zidovudine, 1041, 1042
treatment of infected PBL with immunoglobulins, 563
vaccine
subunit, clinical and immunologic responses, 1288
vaccinia virus recombinant, 782
Human papillomavirus
detection, by PCR, 1077
editorial, 1075
high-risk, detection in cervix and semen of sex partners, 682
infection
cervical-vaginal and intraanal, in young girls, 339
condylomata acuminata, detection of HPV types, 759
genital, risk factors, 753
type-specific, persistence in women, 498
novel sequence, 1086, 1089, 1093, 1096
type 16, antibody, in cervical cancer, 1424
Human T cell lymphotropic virus type I
genotyping, by PCR, viral evolution and dissemination, 1353
and II, and HIV-1, infections, in Hansen's disease, 1007
specific T cell responses, by PCR, 334
transmission, insect, 44
Human T cell lymphotropic virus type II, transmission in HTLV-I–screened blood products, 206
Hyaluronidase, of *A. caninum* and *A. simplex*, role in pathogenesis, 918

Idiopathic $CD4^+$ lymphocytopenia, in IVDUs, 748
IDSA annual meeting
preliminary information, 502

presentation
chronic fatigue syndrome, 1
HIV-1 pathogenesis, 286
new technology, clinical microbiology laboratory, 1068
T. gondii, encephalitis, immunopathogenesis, 1057
symposium
cholera pandemic, emergence, 278
emerging infectious diseases, 263, 265
Immunoglobulins
cationized human, for HIV-1–infected lymphocytes, 563
intestinal, in HIV-1 infection, 299
Infectious diseases, emergence and reemergence, 263, 265, 272, 278, 284
Influenza A virus
potentiation and pathogenesis, by dust mite protease, 1023
vaccine, genetic intrastrain variation, 1432
Influenza virus, infection, heterotypic immunity, mouse model, 1195
Interferon-α, effect on neutrophil response, to influenza a virus and FMLP, 802
Interferon-γ
plus antimony, for visceral leishmaniasis, 659
in Boutonneuse fever, 1637
for *C. neoformans* infection, mouse model, 1331
effect on PMNL activity against *A. fumigatus*, 894
in HSV encephalitis, 678
production, in lymphocytic choriomeningitis, mouse model, 1189
in *T. gondii*, encephalitis, levels, mouse model, 939
Interleukin
in HIV infection, effects of IL-2 on CD4 cell count, 1044
production in leishmaniasis, 1037
response, in *O. volvulus* infection, after ivermectin, 962
Interleukin-1, production, in dengue virus infection, 811
Interleukin-6
effect of ivermectin on, in onchocerciasis, 663
in HSV encephalitis, 678
production, in lymphocytic choriomeningitis, mouse model, 1189
Interleukin-8, role in neutrophil recruitment, in *T. vaginalis* infection, 1638
Interleukin-10, filarial antigen–induced, 403
Ivermectin for *O. volvulus* infection
cytokine response, 962
effect on C-reactive protein and IL-6, 663

Lactobacilli, H_2O_2-producing, effect on *N. gonorrhoeae*, 1209
Leishmaniasis, visceral
and cutaneous, cytokine production in, 1037
refractory, antimony plus IFN-γ for, 659
rhGM-CSF for, 413
Leukemia inhibiting factor, levels in meningococcemia, correlation with disease severity, 1224
Ligase chain reaction, to diagnose urethral *C. trachomatis* infection, 1308
Lipopolysaccharide
binding
and neutralization, 1490
protein, role in TNF response of monocytes to LPS, 1319
H. pylori, neutrophil activation by, 135
Listeria monocytogenes
growth in mice injected with TNF, 234
outbreak, 693
Liver transplantation, invasive fungal infections, risk factors, 644
Lyme disease
arthritis, reactive, 978
and babesiosis, acquisition, risk from blood transfusion, 231
B. burgdorferi, seroprotective groups, 115
enzootic cycle of *B. burgdorferi*, in Colorado, 636
transmission, role of dormice, 122
Lymphocytic choriomeningitis virus, infection, superantigen shock, mouse model, 1189

Macrorestriction DNA analysis, to type *H. pylori*, 473
Malaria
acquisition, reducing risk in travelers, 257
falciparum, chloroquine for, 258
Measles virus
infection
children's vaccine initiative report, S63
control programs, S32
economic analysis of control programs, S56
pathogenesis and immune response, S24
state of art and future directions, S3
stopping serial killer, S1
susceptibility, in young American adults, 216
replication and immunity, macaque model, 443
vaccines, development and strategies, S42
virology, S15
wild type and vaccine strains, antigenic analysis, 795
Monoclonal antibody to
bactericidal/permeability increasing protein, 1483
HIV-1 gp120 V3 loop, phase I/II study, 1384
Monocyte, response to *T. beigelii*, 1557
Mononuclear phagocytes, HIV-1-infected, anticryptococcal activity, 60
Mononucleosis, acute infectious, EBV DNA in serum, 436
Moraxella catarrhalis
expression of antigenically conserved protein, 867
and *H. influenzae*, pneumonia, diagnosis by serology, 220
induced penicillin neutralization, in pneumococcal pneumonia, mouse model, 1613
MT-2 cell tropism, as prognostic marker, in HIV-1 infection, 1367
Muerto Canyon virus, RNA, in PBMC of patients with hantavirus pulmonary syndrome, 1013
Mycobacterium avium, replication in macrophages, effect of hypertrigylceridemic serum, lipoprotein, and iron, 1248
Mycobacterium avium complex, infection in AIDS, 157, 362, 488, 573, 578, 1601
Mycobacterium avium–M. intracellulare complex, infection, in AIDS, effect of pentoxifylline on TNF-α, 484
Mycobacterium tuberculosis
detection by PCR, in pulmonary infection treatment, 713
estimated age, 1348
fluoroquinolone-resistant mutant, 479
infection, vs. BCG vaccination, differential T cell responses, 1326
intracellular growth in monocytes, effect of TGF-β1, 1229
stimulated monocytes, expression of chemokines, 1238
Mycoplasma pneumoniae, detection by PCR, in fixed lung tissue, 1051

Neisseria gonorrhoeae
growth and catalase activity, effect of H_2O_2-producing lactobacilli, 1209
infection, and *T. pallidum*, infection, comparison of treatment regimens, 689
non–penicillinase-producing strains, genetic relatedness, 696
Neisseria meningitidis
infection, LIF levels in, correlation with disease severity, 1224
sepsis and meningitis, penicillin resistant, 453
septic shock, in children, Fcγ receptor polymorphism, 848
vaccine, effect on neutrophil killing, in complement-deficient patients, 449
Nematode
hyaluronidases, role in pathogenesis of human disease, 918
infection, lymphatic abnormalities in human disease, 927

Nitric oxide, production and neurotoxicity, mediated from human and mouse brain, 457
Nitric oxide synthase, and human macrophages, 744, 745
Norwalk virus, gastroenteritis, volunteer study, 34

Ocular infection, *C. trachomatis*, PCR for detection, 709
Onchocerca volvulus infection
antibody response, 955
cytokine response, after ivermectin, 962
endemic and nonendemic populations, clinical and immunologic findings, 736
in hyperendemic areas, 1054
ivermectin effect on C-reactive protein and IL-6, 663
Otitis media
H. influenzae, nontypeable, chinchilla model, 1532
recurrent, and *H. influenzae* nasopharyngeal colonization, 862
Outer surface protein A, *B. burgdorferi*, quantitation during life cycle, 883

p24 antigen, in HIV-1 infection, in infants, 318
p55 TNF receptor immunoadhesin, protection against endotoxic shock, rat model, 1323
Papillomavirus, human
antibody, in cervical cancer, 1424
detection by PCR, 1077
editorial, 1075
high-risk, detection in cervix and semen of sex partners, 682
infection
cervical-vaginal and intraanal, in young girls, 339
condylomata acuminata, detection of HPV types, 759
genital, risk factors, 753
type-specific, persistence in women, 498
novel sequences, 1086, 1089, 1093, 1096
Paromomycin for *C. parvum*
diarrhea, in AIDS, 419
infection, vs. aminoglycosides and azithromycin, immunosuppressed rat model, 934
Parvovirus B19, detection by PCR, 1047
Penicillin-binding proteins, effect of acylation on postantibiotic effect, 609
Pentoxifylline, effect on TNF-α and MAC growth, in AIDS, 484
Perspective, antimicrobials, oral, over-the-counter availability, 1256
Phagocyte activity, correlation with clinical status, 1463
Plasmodium falciparum
multidrug resistant, artesunate-mefloquine for, 971
treatment failure, predicted by PCR, 1626
vaccine, synthetic, 396
Plasmodium vivax–like malaria parasite, in blood samples, 1630
Pneumocystis carinii infection
evaluation of 10 drugs against, rat model, 906
pneumonia, in AIDS, treatment, 165, 912
and toxoplasmosis, combined prophylaxis, mouse model, 653
Pneumonitis, *C. pneumoniae*, lung ultrastructure, mouse model, 464
pol gene, HIV-1, resistance mutations, in blood and semen, 1292
Polymerase chain reaction to detect
CMV, 1264, 1271
C. trachomatis, 500, 709
HIV-1 tissue burden, 325
HPV, 1077
HTLV-1–specific T cell responses, 334
human parvovirus B19, 1047
M. pneumoniae, in fixed lung tissue, 1051
M. tuberculosis, in pulmonary infection treatment, 713
Muerto Canyon virus RNA, 1013
parasitemia, in *T. cruzi* infection, 1334
P. falciparum DNA, to monitor treatment, 1626
P. vivax CS gene, 1630
V. cholerae toxin genes, 750
Polymorphonuclear leukocyte
interaction, with *Y. enterocolitica*, role of virulence plasmid and desferrioxamine B, 140
killing, of *P. aeruginosa*, effect of TNFα, 82
response, to *T. beigelii*, 1557
Pregnancy, vaginal flora changes, association with preterm birth, 724
Prosthetic infection, *S. epidermidis*, vancomycin for, 720
Pseudomonas aeruginosa
exotoxin, for HIV-1 infection, 1180
infection
chronic, in cystic fibrosis, 1616
outbreak, in burn unit, multiply resistant strains, 377
PMNL killing, effect of TNFα, 82
Pseudomonas cepacia, infection, in CGD, nonoxidative killing, 1524
Puumala virus, new strain, severe HFRS, 1456

Respiratory syncytial virus
stimulation of human PBMC, cytokine response, 1201
surveillance, 1985–1990, in US, 986
vaccine, subunit, immune response, 345, 425
Respiratory tract infection, recurrent, in children, Fcγ receptor, phenotype distribution, 854
Retinitis, CMV, in AIDS, treatment, ACTG trial, 189
Rotavirus, vaccine, tetravalent, in young infants, 1260
Rubella, vaccines and vaccination report, 507

Salmonella infection, antimicrobial-resistant, incidence in US, 128
Salmonella typhi, vaccine, cytokine production and lymphoproliferative responses, 1508
Schistosoma japonicum, infection, hepatic pathology, in SCID-hu mice, 733
Schistosoma mansoni, infection, cytokine response, in humans, 946
Seoul hantavirus, seropositivity, among IDUs, 1636
Sepsis
E. coli, 622, 630
gram-negative, 1473, 1490
Septic shock
anti-TNF for, rat model, 1323
N. meningitidis, in children, Fcγ receptor polymorphism, 848
Simian immunodeficiency virus, vaccine, inactivated, in macaques, 51
Staphylococcus aureus
arthritogenicity, TSST-1 effect, 94
gentamycin-resistant auxotrophs, persistence in endothelial cells, 1033
TSST-1 and SEB production, 818
Staphylococcus epidermidis infection
methicillin-resistant, endocarditis, treatment, 100
prosthetic, vancomycin penetration, 720
Stavudine, for HIV-1 infection, genotypic and phenotypic viral analysis, after prolonged therapy, 1157
Streptococci, group A, mitogen, proliferative response of PBMC, 585
Streptococci, group B
carriage in pregnant mothers and infants, in Gambia, 1316
neutrophil killing, 88
Streptococcus pneumoniae
degradation of C3, 600
invasive disease, in Alaska, 368
opsonization and antibodies to polysaccharides, 592
pneumonia, *M. catarrhalis*–induced penicillin neutralization, mouse model, 1613
serotypes and antimicrobial resistance patterns, in Alaska, 461

Streptococcus pyogenes, postantibiotic effect, 609
Syphilis, *See Neisseria gonorrhoeae* infection

T cell response to
  live attenuated dengue virus type 2 vaccine, 27
  mycobacteria-secreted proteins, 1326
Teicoplanin, for bacteremia, in cancer, 1344
Toxic shock syndrome toxin-1, *S. aureus*, 818
Toxoplasma gondii infection
  encephalitis
    cytokines in lymph nodes and brain, mouse model, 939
    immunopathogenesis, 1057
  and pneumocystosis, combined prophylaxis, mouse model, 653
Transforming growth factor-β1, effect on *M. tuberculosis* growth, 1229
Treponema pallidum, infection, and *N. gonorrhoeae* infection, comparison of treatment regimens, 689
Tribute, Sheldon M. Wolff, 261
Trichomonas vaginalis infection
  intravaginal vs. oral metronidazole for, 242
  neutrophil recruitment, IL-8 role, 1638
Trichosporon beigelii, PMNL and monocyte response, 1557
Trypanosoma cruzi
  infection, chronic, PCR to detect kDNA minicircles, 1334
  trans-sialidase, antibodies to, 1570
Tuberculosis, multidrug-resistant, in New York prison system, 151
Tularemia, *F. tularensis*, immunity after natural infection, 110
Tumor necrosis factor
  antibody, effect on granulocyte and monocyte flux into inflammatory exudate, mouse model, 234
  LPS-induced monocyte release, 1319
  production, in leishmaniasis, 1037
  in *T. gondii*, encephalitis, levels, mouse model, 939
Tumor necrosis factor-α
  in HSV encephalitis, 678
  inhibition, and MAC growth, in AIDS, 484

Ulcers, genital, in women, risk of HIV-1 infection, 313

Vaccine against
  BCG, in healthy adults, 476
  dengue virus, 27, 1448
  E. coli, polyvalent, safety and immunogenicity, 834
  HBV, effect of age on immunogenicity, 510
  H. influenzae type b
    anti–PRP antibody levels, 1050
    tetanus toxoid conjugate, 76
  HIV-1, 782, 1288
  HSV-2, using mutant type, 1100
  influenza A, genetic intrastrain variation, 1432
  N. meningitidis, effect on neutrophil killing, in complement-deficient patients, 449
  P. falciparum, 396
  rotavirus, in young infants, 1260
  RSV, subunit, immune response, 345, 425
  rubella, report, 507
  SIV, in macaques, 51
  S. typhi, cytokine production and lymphoproliferative responses, 1508
  varicella, live attenuated, response in elderly, 522
  V. cholerae
    El Tor, 1518
    live prototype, 278
Vancomycin for
  bacteremia, in cancer, 1344
  S. epidermidis infection, prosthetic, 720
Varicella-zoster virus
  infection, in pregnancy, 991
  resistance to acyclovir, 68
  vaccine, live attenuated, response in elderly, 522
Vibrio cholerae
  distribution of toxin genes, 750
  El Tor, vaccine, live attenuated, 1518
  infection, severe, association with blood group O in Peru, 468
  O1, relatedness of epidemic strain O139, 701
  pandemic, virulence determinants, 278
Visceral leishmaniasis, refractory, antimony plus IFN-γ for, 659

Wolff, Sheldon M., Tribute, 261
Wucheria bancrofti infection
  lymphatic abnormalities in human disease, 927
  Og4C3 antigen, marker of infection and worm burden, 247

Yellow fever virus, congenital infection, detection, 251
Yersinia enterocolitica, PMNL interaction, role of virulence plasmid and desferrioxamine B, 140

Zidovudine for HIV-1 infection
  B and T cell function, 1148
  and didanosine, resistance, HIV-1 in blood and semen, 1292
  effect on immune activation, 1165
  in vitro antibody production, 1376
  MT-2 cell tropism as marker for treatment response, 1367